The world’s biggest hearing aid manufacturer, Swiss Sonova, on Tuesday downgraded its full-year expectations for 2022/2023, citing a weak private market in the US and high freight and component costs.
In particular, the developments in the US are worrying when it comes to some of Sonova’s competitors based in Denmark, says Sydbank analyst Søren Løntoft Hansen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
CMC Writer 
Drug Safety Associate 
Lab Manager 
Pharmacovigilance & Regulatory Officer 
Senior Director Translational Pharmacology 
Quality Assurance & Regulatory Affairs Manager 
KLIFO is looking for QA Specialist/Senior QA Specialist, GCP and GVP for our Glostrup office 
Nordic Key Account Manager, Hollister & Dansac 
Principal Scientist - Drug Metabolism & Pharmacokinetics 
Senior CMC Regulatory Manager 
Scientist Radiochemistry